[144] ACUREN CORP SEC Filing
Rhea-AI Filing Summary
TIC reports a planned sale of restricted or control securities under Rule 144. A company affiliate intends to sell 52,467 common shares through Merrill Lynch, Pierce, Fenner & Smith Inc. on the NYSE, with an approximate aggregate market value of 500006.21. The sale is expected to occur around 11/18/2025.
The notice states that there were 220,559,713 common shares outstanding at the time referenced. The shares to be sold were acquired from the issuer as compensation on several dates, including 08/04/2025 (29,534 shares), 07/28/2025 (13,906 shares), and 03/03/2025 (9,026 shares), with payment also characterized as compensation. The signer represents that they are not aware of undisclosed material adverse information about TIC.
Positive
- None.
Negative
- None.
FAQ
What does TIC's latest Form 144 filing report?
TIC's Form 144 notice reports that an affiliate plans to sell 52,467 shares of common stock on the NYSE through Merrill Lynch, Pierce, Fenner & Smith Inc., with an approximate aggregate market value of 500006.21.
When is the TIC Form 144 sale expected to take place?
The notice lists an approximate date of sale of 11/18/2025 for the planned disposition of 52,467 TIC common shares.
Does the TIC Form 144 include any representation about undisclosed information?
Yes. By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about TIC's current or prospective operations that has not been publicly disclosed.